16,248 Shares in Icon Plc $ICLR Acquired by OVERSEA CHINESE BANKING Corp Ltd

OVERSEA CHINESE BANKING Corp Ltd acquired a new position in Icon Plc (NASDAQ:ICLR) in the 4th quarter, Holdings Channel reports. The firm acquired 16,248 shares of the medical research company’s stock, valued at approximately $2,960,000.

Several other hedge funds also recently added to or reduced their stakes in ICLR. WINTON GROUP Ltd purchased a new position in Icon in the second quarter worth approximately $254,000. Daiwa Securities Group Inc. grew its position in Icon by 19.3% in the second quarter. Daiwa Securities Group Inc. now owns 28,145 shares of the medical research company’s stock worth $4,094,000 after acquiring an additional 4,546 shares during the period. Frontier Capital Management Co. LLC grew its position in Icon by 97.6% in the second quarter. Frontier Capital Management Co. LLC now owns 71,360 shares of the medical research company’s stock worth $10,379,000 after acquiring an additional 35,253 shares during the period. Peapack Gladstone Financial Corp purchased a new position in Icon in the second quarter worth approximately $212,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Icon by 58.7% in the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 781 shares of the medical research company’s stock worth $113,000 after acquiring an additional 289 shares during the period. 95.61% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on ICLR. Rothschild & Co Redburn set a $100.00 price objective on Icon and gave the stock a “neutral” rating in a research report on Tuesday, February 17th. BMO Capital Markets upgraded Icon from a “market perform” rating to an “outperform” rating and raised their price target for the stock from $100.00 to $130.00 in a research report on Thursday, March 26th. Barclays lowered their price target on Icon from $200.00 to $120.00 and set an “equal weight” rating for the company in a research report on Monday, March 9th. Weiss Ratings lowered Icon from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Wednesday, March 18th. Finally, Mizuho set a $216.00 price target on Icon in a research report on Friday, January 9th. Seven equities research analysts have rated the stock with a Buy rating, seven have given a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $148.80.

Icon Trading Up 0.2%

ICLR opened at $115.43 on Thursday. Icon Plc has a 52 week low of $66.57 and a 52 week high of $211.00. The business has a fifty day simple moving average of $105.02 and a 200-day simple moving average of $152.27. The firm has a market cap of $9.32 billion, a P/E ratio of 15.62, a P/E/G ratio of 2.91 and a beta of 1.28. The company has a quick ratio of 1.06, a current ratio of 1.06 and a debt-to-equity ratio of 0.31.

About Icon

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.